đđĽđ¨đđđĽ đđđ-đ đđđĽđĽ đđĄđđŤđđŠđ˛ đđđŤđ¤đđ
The global CAR-T cell (Chimeric Antigen Receptor-T Cell Therapy) market was valued at USD 5.2 billion in 2024 and is projected to reach USD 26.2 billion by 2030. The market is expected to grow at a CAGR of 31% during the forecast period, 2025-2030. đđđ-đ đđđĽđĽ đđĄđđŤđđŠđ˛ đđđŤđ¤đđ đđđŠđ¨đŤđ đđ˘đ§đ¤: https://www.wissenresearch.com/car-t-cell-therapy-market/ đđŤđ¨đŚđ˘đ§đđ§đ đđĽđđ˛đđŤđŹ đđ˘đđĄđ˘đ§ đđđ-đ đđđĽđĽ đđĄđđŤđđŠđ˛ đđđŤđ¤đđ ⢠Bristol-Myers Squibb Company (US) ⢠Novartis AG (Switzerland) ⢠Gilead Sciences, Inc. (US) ⢠Johnson & Johnson. (US) ⢠JW Therapeutics (Shanghai) Co., Ltd. (China) ⢠bluebird bio, Inc. (US) ⢠Merck & Co., Inc. (US) ⢠Sangamo Therapeutics (US) ⢠Sorrento Therapeutics, Inc. (US) ⢠GSK plc. (UK) ⢠ImmunoACT Pvt Ltd (India) ⢠CARsgen Therapeutics Holdings Ltd. (China) ⢠IASO Biotherapeutics. (China) đđŹđ¤ đđ¨đŤ đđŽđŹđđ¨đŚđ˘đłđđ đŤđđŠđ¨đŤđ: https://www.wissenresearch.com/ask-for-customization/











